Claudio Hidalgo Cantabrana, PhD, CEO at Microviable, and Pilar Manrique, PhD, Research Scientist, will be attending the 8th Microbiome Movement – Drug Development Summit Europe which will take place from 30 January to 1 February 2024 in Barcelona. The event will cover the most exciting progress in the microbiome world, from expanded analytics and larger-scale manufacturing to the most pressing challenges from translation to regulations.
Pilar Manrique will speak about how to develop a donor-derived microbiome product for infectious diseases (“Revealing a Donor-Derived Microbiome Product for Infectious Disease Beyond the Gut”. Tuesday 30th at 9:30 a.m.). On the other hand, Claudio Hidalgo will participate in the roundtable “Dive into Discussions to Explore Your Topic of Interest” (Tuesday 30 at 4:15 a.m.).
Microviable develops novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. Microviable is a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
